Tien Liang Biotech Co., Ltd. AI Stock Analysis
Tien Liang Biotech Co., Ltd. (4127) AI Stock Analysis
Tien Liang Biotech Co., Ltd.
(TPEx:4127)
The stock scores at the lowest possible level, reflecting a convergence of severe fundamental and market risks. The primary driver is the company's precarious financial state, marked by unprofitability, a dangerous debt load, and collapsing cash flow. This is compounded by extremely weak technicals, with the stock in a clear downtrend and showing no signs of reversal. The valuation offers no support, as the P/E ratio is distorted by losses and there is no dividend. The overall risk profile is exceptionally high.
Tien Liang Biotech Co., Ltd. (4127) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 1.59B
- Dividend Yield
- ―
- Average Volume (3M)
- 274.15K
- Price to Earnings (P/E)
- 23.0
- Beta (1Y)
- 0.35
- Revenue Growth
- 46.74%
- EPS Growth
- ―
- Country
- TW
- Employees
- 88
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Tien Liang Biotech Co., Ltd. Business Overview & Revenue Model
Company Description
Tien Liang BioTech Co., Ltd., established in 1960 and headquartered in New Taipei City, Taiwan, is a pharmaceutical enterprise involved in the development, manufacturing, and global distribution of a diverse array of health and medicinal products. Th...
Tien Liang Biotech Co., Ltd. Financial Statement Overview
Summary
Financial health has deteriorated sharply. The company swung to a net loss with negative EBIT and EBITDA margins, debt-to-equity surged to a risky 1.26, and free cash flow plummeted 66.7%. The combination of negative profitability, high leverage, and weakening cash flow presents significant risk.
Income Statement
35NegativeBalance Sheet
30NegativeCash Flow
40Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 650.87M | 511.79M | 385.21M | 459.99M | 528.52M | 571.32M |
| Gross Profit | 376.74M | 277.86M | 229.91M | 286.15M | 336.55M | 338.28M |
| EBITDA | 40.79M | -6.07M | 25.49M | 31.05M | 72.15M | 63.06M |
| Net Income | 69.09M | -10.25M | 11.70M | 17.73M | 59.48M | 46.60M |
Balance Sheet | ||||||
| Total Assets | 1.22B | 1.18B | 888.68M | 654.03M | 676.43M | 655.35M |
| Cash, Cash Equivalents and Short-Term Investments | 197.10M | 152.31M | 130.67M | 142.22M | 107.84M | 118.47M |
| Total Debt | 598.00M | 598.54M | 345.20M | 84.66M | 114.13M | 156.87M |
| Total Liabilities | 704.10M | 709.19M | 410.76M | 161.05M | 201.30M | 241.30M |
| Stockholders Equity | 519.25M | 474.04M | 477.92M | 492.98M | 475.13M | 414.05M |
Cash Flow | ||||||
| Free Cash Flow | 37.54M | 14.33M | 44.20M | 64.33M | 20.87M | 44.61M |
| Operating Cash Flow | 60.37M | 37.52M | 48.34M | 69.67M | 21.88M | 45.21M |
| Investing Cash Flow | -121.75M | -299.22M | -301.51M | -4.78M | -1.21M | -1.18M |
| Financing Cash Flow | 67.44M | 253.34M | 241.62M | -30.52M | -31.30M | -40.80M |
Tien Liang Biotech Co., Ltd. Peers Comparison
Overall Rating
TW:411176Outperform
TW:129559Neutral
TW:684655Neutral
TW:412737Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 76Outperform | TWD 1.71B | 9.18 | ― | 4.55% | 5.33% | 13.75% | |
| 59Neutral | TWD 1.58B | 10.22 | ― | 7.10% | 2.80% | -22.52% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 55Neutral | TWD 1.36B | 12.85 | ― | 7.87% | -3.09% | -27.23% | |
| 37Underperform | TWD 1.59B | 23.02 | ― | ― | 46.74% | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4127 | Tien Liang Biotech Co., Ltd. | 34.80 | 3.80 | 12.26% | |
| TW:1295 | Synbio Tech Inc | 42.10 | -48.12 | -53.34% | |
| TW:4111 | Chi Sheng Pharma & Biotech Co., Ltd. | 28.55 | 0.13 | 0.47% | |
| TW:6846 | Greenyn Biotechnology Co., Ltd. | 50.10 | -21.61 | -30.14% | |
| TW:6886 | Far East Bio-Tec. Co., Ltd. | 37.85 | -4.19 | -9.96% | |
| TW:7806 | Gin Hwa Biotech, Inc. | 48.00 | -11.22 | -18.94% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026
